Sarepta's Additional Data Doesn't Sway FDA On Eteplirsen
Agency reviewers raise more concerns about efficacy of proposed Duchenne muscular dystrophy treatment despite new information.
Agency reviewers raise more concerns about efficacy of proposed Duchenne muscular dystrophy treatment despite new information.